Stem Cell Therapies Facing Commercial Challenges Despite Promising Pipeline, Says GBI Research

Jul 21, 2016, 09:01 ET from GBI Research

LONDON, July 21, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape - states that while steady progress in clinical research and increasing evidence of product effectiveness are significant driving factors for growth in the stem cell therapies market, a number of obstacles remain before they become widely commercially viable.

The stem cell therapy pipeline as a whole is relatively large, with 330 products in active development across all stages. Indeed, R&D within the sector is gaining momentum as candidates move into clinical development, and the results of clinical studies become apparent, clarifying the therapeutic potential of stem cell therapy.

Managing Analyst Rodrigo Gutierrez Gamboa says: "The stem cell space provides therapeutic potential in indications where current pharmacological and surgical treatment options are ineffective. However, there remains a significant divide between the number of stem cell therapeutic applications currently available for patients and the number of research programs investigating the wider medical applications of stem-cell-based therapies.  

"Stem cells are currently being used for a modest variety of indications, with skin and blood stem cells representing the majority of therapeutic uses. The stem cell industry is pursuing a broad base of therapeutic applications, and this is evident in the R&D efforts observed in the sector as over 15 therapy areas are being targeted by the stem cell industry in over 1,000 clinical trials."

Despite promising recent developments within the field of stem cell technology, converting its scientific potential into real therapeutic value still represents a significant challenge.

GBI Research's survey of key opinion leaders revealed that the stem cells field is still surrounded by a wide variety of obstacles, most notably the high cost of research, which participants stated was the biggest factor limiting stem cell progress.

Gutierrez Gamboa concludes: "Manufacturers will need to adopt novel strategies to realize their full potential. It is likely that manufacturing methodologies will use partially or fully automated systems in future approaches, in order to improve yield, purity and cost-effectiveness.

"There have been good strides made by stem cell manufacturing companies, such as those made by Cynata Therapeutics, which is implementing innovative manufacturing methods to generate robust, consistent and inexpensive stem cells. Such companies are pointing towards a promising outlook in this regard."

Sample pages of GBI Research's report Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape are available upon request.

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44 161 359 5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter